Altimmune (ALT) Receivables (2010 - 2026)

Altimmune (ALT) has 17 years of Receivables data on file, last reported at $3.1 million in Q1 2026.

• On a quarterly basis, Receivables rose 237.93% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 237.93% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 145.66% from the prior year.
• Receivables for Q1 2026 stood at $3.1 million, up from $2.3 million in the prior quarter.
• Over the last five years, Receivables for ALT reached as high as $3.1 million in Q1 2026 and fell as low as $136000.0 in Q2 2023.
• Historically, Receivables has averaged $866411.8 across 5 years, with a median of $724000.0 in 2024.
• Across the five-year window, Receivables plunged 95.98% in 2022 and surged 600.0% in 2023, its largest moves.
• Year by year, Receivables stood at $173000.0 in 2022, then jumped by 600.0% to $1.2 million in 2023, then fell by 22.05% to $944000.0 in 2024, then surged by 145.66% to $2.3 million in 2025, then surged by 32.17% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $3.1 million in Q1 2026, $2.3 million in Q4 2025, and $1.5 million in Q3 2025.